Copyright © DrugPatentWatch. Initially printed at New patent for Novartis drug RYDAPT
Annual Drug Patent Expirations for RYDAPT
Rydapt is a drug marketed by Novartis and is included in a single NDA. It’s out there from one provider. There are three patents defending this drug.
Drug patent litigation for RYDAPT.
This drug has fifty-five patent relations in twenty-seven international locations.
The generic ingredient in RYDAPT is midostaurin. One provider is listed for this compound. Extra particulars can be found on the midostaurin profile web page.
For extra data on how DrugPatentWatch may also help together with your pharmaceutical enterprise intelligence wants, contact admin@DrugPatentWatch.com or go to www.DrugPatentWatch.com
Make Higher Choices with DrugPatentWatch
Copyright © DrugPatentWatch. Initially printed at New patent for Novartis drug RYDAPT